$XBI $130.51 -0.61%
Covid Updates
$COCP +3.6% Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses. source
$ENDP +3.4% Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care. source
Pipeline Updates
$OCGN -6.0% Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration source
$TNXP +1.6% Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021 source
$DRRX +4.8% DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021. source
$DMAC -1.1% DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial. source
$TFFP -2.2% TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients. source
$ACXP +4.5% Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference. source
$PIRS -2.6% Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012. source
$CRIS -4.1% Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. source
$SEEL +3.6% Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia. source
$IMRA -2.9% Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). source
$KALV -1.4% KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE. source
$AFMD -6.2% Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01. source
$CYDY -0.9% CytoDyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab as a Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC); Fast Track Designation for mTNBC was received previously. source
$ETON -10.7% Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral Solution. source
$LQDA +4.1% FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder. source
$HCM +0.3% HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting. source
$IONS +3.5% Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting. source
Financial Updates
$KDNY -11.1% CHINOOK THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK source
Posted by FS/JM
Comments